CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access
{{output}}
Chimeric antigen receptor T-cell (CAR-T) immunotherapy has revolutionized the treatment of hematologic malignancies, especially in B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, and multiple myeloma. However, inequitable access to CAR T-cell... ...
